ReviewAmerican journal of translational research2024
Meta-analysis of the correlation between inflammatory response indices and no-reflow after PCI in patients with acute STEMI.
Review in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Assessment of inflammatory and glycemic markers for in-hospital mortality in STEMI patients.Irish journal of medical science · 2026Article
- Risk factors for Post-PCI cardiovascular events in coronary artery disease patients treated with clopidogrel combined with aspirin.Frontiers in pharmacology · 2026Article
- Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study.Journal of the American Heart Association · 2025Article
- No-Reflow During Coronary Interventions: A Narrative Review.Journal of clinical medicine · 2025Review
- Neutrophil Percentage/Albumin Ratio as an Independent Predictor of the No-Reflow Phenomenon in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.Diagnostics (Basel, Switzerland) · 2025Article
- Reperfusion injury in STEMI: a double-edged sword.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Review
- Atherogenic Index of Plasma Predicts Futile Reperfusion and Early Deterioration After Successful Recanalization: A Multicenter Study of EVT-Treated LAA Stroke.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAfter percutaneous coronary intervention (PCI), patients with acute ST-segment elevation myocardial infarction (STEMI) could have an inflammatory response, which may lead to the risk of no-reflow due to microvascular obstruction. However, the association between changes in the levels of inflammatory response-related factors and no-reflow after PCI in patients with acute STEMI is still controversial.
methodsIn this study, a meta-analysis was conducted. Studies from the database established before April 2024 were retrieved in PubMed, Web of Science, and EMBASE. Case-control or cohort studies were included. Repetitive publications, studies without full access and successful data extraction, fragmentary information, animal experiments, summary, and systematic reviews were excluded, and Review Manager 5.3 software was used to process the data.
resultsThe meta-analysis showed that elevated levels of high-sensitivity C-reactive protein (Hs-CRP) (
conclusionRefined results of Hs-CRP, PLR, RDW, leukocytes, and neutrophil can provide clinicians with effective tools to reduce the risk of no-reflow in patients with acute STEMI after PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.